Articles From: Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors to NAB's Great Western IPO Prices Below Expectations


EpiPen® Auto-Injector Locations Designated on Updated Guide Maps and Signage New Multi-year Alliance to Increase Anaphylaxis Awareness through Multiple Educational Initiatives PITTSBURGH , Nov.
Sign-up for Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors investment picks
2014 Adjusted Diluted EPS Guidance Range Increases to $3.54 to $3.60 PITTSBURGH , Oct.
Sign-up for Mylan Third Quarter 2014 Adjusted Diluted EPS Increases 41% to $1.16 investment picks
Provides Another Important and Highly Complex Injectable to Complement Mylan Institutional's Growing Portfolio in the U.S. PITTSBURGH , Sept.
Sign-up for Mylan to Acquire U.S. Rights to Arixtra® (fondaparinux sodium) Injection from Aspen investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156044&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Announces Positive Safety Data Demonstrating Fortetropin's(TM) Lack of Adverse Effect on Serum Lipids and Cholesterol Levels investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1145602&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM) investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1155092&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Announces Statistically Significant Top-Line Clinical Data Demonstrating Fortetropin's(TM) Anti-Inflammatory BioTherapeutic Properties investment picks
- Patent will protect MYOS' intellectual property portfolio for Fortetropin through 2033 – CEDAR KNOLLS, N.J., July 24, 2014 (GLOBE NEWSWIRE) -- MYOS Corporation ("MYOS" or the "Company") (Nasdaq:MYOS) , an emerging biotherapeutics and bionutrition company focused on the discovery, development and commercialization of products that improve muscle health and performance, announced today that it recently received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for U.S. Patent Application Serial No.
Sign-up for MYOS Corporation Receives Notice of Allowance of U.S. Patent Application for Proprietary Manufacturing Methods of Fortetropin investment picks
http://media.marketwire.com/attachments/201408/78060_MYOS.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1137787&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Reports 2014 Second Quarter Results investment picks
http://media.marketwire.com/attachments/201408/78060_MYOS.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1141994&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation to Present at the Rodman & Renshaw 16th Annual Global Investment Conference on September 10, 2014 investment picks
ROLLING MEADOWS, Ill., July 30, 2014 (GLOBE NEWSWIRE) -- MYR Group Inc. ("MYR Group") (Nasdaq:MYRG) , a leading specialty contractor serving the electrical infrastructure market, announced it will release second-quarter 2014 results on Wednesday, August 6, 2014, after the close of trading.
Sign-up for MYR Group Inc. Announces Second-Quarter 2014 Earnings Release and Conference Call Schedule investment picks
ROLLING MEADOWS, Ill., Aug.
Sign-up for MYR Group Inc. Announces Second-Quarter and First-Half 2014 Results investment picks
ROLLING MEADOWS, Ill., Nov.
Sign-up for MYR Group Inc. Announces Third-Quarter and First Nine-Months 2014 Results investment picks
SALT LAKE CITY, Nov.
Sign-up for Myriad and AbbVie Sign Expanded Agreement for Tumor BRACAnalysis CDx(TM) investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Announces Inclusion of Prolaris(R) Test in NCCN Guidelines investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Appoints R. Bryan Riggsbee as Chief Financial Officer investment picks
SALT LAKE CITY and ZURICH, Oct.
Sign-up for Myriad Establishes Tumor BRACAnalysis CDx(TM) Laboratory in Europe investment picks
Revenue of $168.8 million; diluted EPS of $0.21; adjusted EPS of $0.25 myRisk Hereditary Cancer revenue of $53.1 million, up 95 percent sequentially Draft Medicare decision covering Prolaris for low-risk prostate cancer patients CHMP recommends approval of olaparib in ovarian cancer patients with BRCA mutations Company reiterates fiscal year 2015 financial guidance; provides FY2Q15 financial guidance SALT LAKE CITY, Nov.
Sign-up for Myriad Genetics Reports Fiscal First Quarter 2015 Financial Results investment picks
SALT LAKE CITY, Aug.
Sign-up for Myriad Genetics Reports Fiscal Fourth-Quarter and Full-Year 2014 Financial Results investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Genetics to Announce 1Q15 Financial Results on November 4, 2014 investment picks
SALT LAKE CITY, July 30, 2014 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fiscal fourth quarter and full year 2014 as well as provide financial guidance for fiscal year 2015 following the close of market on Tuesday, August 12, 2014.
Sign-up for Myriad Genetics to Announce Financial Results for the Fiscal Fourth Quarter and Full Year 2014 on August 12, 2014 investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Genetics to Present at the 2014 Credit Suisse Annual Healthcare Conference investment picks
SALT LAKE CITY, Aug.
Sign-up for Myriad Genetics to Present at the Morgan Stanley Healthcare Conference investment picks
SALT LAKE CITY, Nov.
Sign-up for Myriad myPath(TM) Melanoma Improves Diagnosis and Treatment Plans investment picks
SALT LAKE CITY, Sept.
Sign-up for Myriad Presents Tumor BRACAnalysis CDx(TM) Study at ESMO investment picks
SALT LAKE CITY, Sept.
Sign-up for Myriad Publishes myRisk Hereditary Cancer Study in Cancer investment picks
SALT LAKE CITY, Oct.
Sign-up for Myriad Receives Draft Medicare Coverage for Prolaris(R) investment picks
2014/10/14
MELBOURNE, Australia--The initial public offering of National Australia Bank Ltd.'s (NAB.AU) regional banking business in South Dakota priced below earlier expectations.
Sign-up for NAB's Great Western IPO Prices Below Expectations investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Mylan Signs Strategic Alliance Agreement with Walt Disney Parks and Resorts to Enhance Access to EpiPen® (epinephrine) Auto-Injectors to NAB's Great Western IPO Prices Below Expectations
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent